Novo Nordisk's Diabetes Drug Shows Promising Results in Alzheimer’s Patients, Reducing Brain Shrinkage by Half
A study found that the diabetes drug liraglutide, made by Novo Nordisk, slowed the progression of Alzheimer's disease by 18% in patients compared to a placebo. Liraglutide also slowed the shrinking of parts of the brain critical for memory and thinking by nearly 50%, according to MRI scans. The drug belongs to a class of diabetes medications called GLP-1s, which are being studied for other health benefits beyond regulating blood sugar and weight loss. Nearly 7 million Americans have Alzheimer's, the 5th leading cause of death for those over 65. Cases are projected to rise dramatically by 2050 without new treatments.
Category
🗞
NewsTranscript
00:00It's Benzinga, and here's what's on the block.
00:02A study found that the diabetes drug loraglitude, made by Novo Nordisk, slowed the progression
00:07of Alzheimer's disease by 18% in patients compared to a placebo.
00:12Loraglitude also slowed the shrinking of parts of the brain critical for memory and thinking
00:16by nearly 50% according to MRI scans.
00:20The drug belongs to a class of diabetes medications called GLP-1s, which are being studied for
00:25other health benefits beyond regulating blood sugar and weight loss.
00:29Nearly 7 million Americans have Alzheimer's, the fifth leading cause of death for those
00:33over 65.
00:34Cases are projected to rise dramatically by 2050 without new treatments.
00:38For all things money, visit Benzinga.com.